Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB

on behalf of the STREAM Sub-study Collaborators

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


BACKGROUND: STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferi- or efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the WHO. The present paper analyses factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the Short regimen. METHODS: This analysis is restricted to 253 participants allocated to the Short regimen and is based on the protocol-defined modified intention to treat (mITT) population. Multivariable Cox regression models were built using backwards elimination with an exit probability of P = 0.157, equivalent to the Akaike Information Criterion, to identify factors independently associated with a definite or probable FoR event. RESULTS: Four baseline factors were identified as being significantly associated with the risk of definite or probable FoR (male sex, a heavily positive baseline smear grade, HIV co-infection and the presence of costophrenic obliteration). There was evidence of association of culture positivity at Week 8 and FoR in a second model and Week 16 smear positivity, presence of diabetes and of smoking in a third model. CONCLUSION: The factors associated with FoR outcomes identified in this analysis should be considered when determining the optimal shortened treatment regimen.

Original languageEnglish
Pages (from-to)753-759
Number of pages7
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number8
Publication statusPublished - Aug 1 2022


  • factors predicting treatment outcome
  • failure or relapse
  • rifampicin-resistant tuberculosis
  • short regimen

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases


Dive into the research topics of 'Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB'. Together they form a unique fingerprint.

Cite this